secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001367644-23-000193
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions to restate 2022 financials after $11.7M tax error; ICFR material weakness
--------------------------------------------------------------------------------

- Audit Committee concluded 2022 audited financials no longer reliable due to $11.7M understatement of income tax benefit.
- Error in net state deferred tax liability calculation; non-cash item impacting 2022 results.
- Material weakness in internal control over financial reporting identified; management's report and EY opinion no longer reliable.
- Company will restate 2022 financials via amended 10-K and file delayed Q3 2023 10-Q as soon as practicable.
- Previously filed Form 12b-25 on Nov 9, 2023 for delayed Q3 report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000193/0001367644-23-000193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000193/ebs-20231116.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer